Towards a molecular basis of oligometastatic disease: potential role of micro-RNAs

Damin DC (2014) Evolving treatment strategies for colo. World J Gastroenterol 20:877–887. doi:10.3748/wjg.v20.i4.877 Giordano SH (2003) Update on locally advanced breast cancer. Oncologist 8(6):521–530 Hellman S, Weichselbaum RR (1995) Oligometastases. J Clin Oncol 13:8–10 Niibe Y, Chang JY, Onishi H, Salama J, Hiraki T, Yamashita H (2013) Oligometastases/oligo-recurrence of lung cancer. Pulm Med 438236–3. doi: 10.1155/2013/438236 Withers HR, Lee SP (2006) Modeling growth kinetics and statistical distribution of oligometastases. Semin Radiat Oncol 16:111–119. doi:10.1016/j.semradonc.2005.12.006 Lussier YA, Khodarev NN, Regan K, Corbin K, Li H, Ganai S, Khan SA, Gnerlich J, Darga TE, Fan H, Karpenko O, Paty PB, Posner MC, Chmura SJ, Hellman S, Ferguson MK, Weichselbaum RR (2012) Oligo-and polymetastatic progression in lung metastasis(es) patients is associated with specific MicroRNAs. PLoS One 7:e50141. doi:10.1371/journal.pone.0050141 Fong Y, Fortner J, Sun RL, Brennan MF, Blumgart LH (1999) Clinical score for predicting recurrence after hepatic resection for metastatic colorectal cancer: analysis of 1001 consecutive cases. Ann Surg 230:309–318 Adam R, De Gramont A, Figueras J, Guthrie A, Kokudo N, Kunstlinger F, Loyer E, Poston G, Rougier P, Rubbia-Brandt L, Sobrero A, Tabernero J, Teh C, Van Cutsem E, Jean-Nicolas Vauthey of the EGOSLIM (Expert Group on OncoSurgery management of LIver Metastases) group (2012) The oncosurgery approach to managing liver metastases from colorectal cancer: a multidisciplinary international consensus. In: Oncologist. pp 1225–1239 Salah S, Watanabe K, Park JS, Addasi A, Park JW, Zabaleta J, Ardissone F, Kim J, Riquet M, Nojiri K, Gisabella M, Kim SY, Tanaka K (2013) Repeated resection of colorectal cancer pulmonary oligometastases: pooled analysis and prognostic assessment. Ann Surg Oncol 20:1955–1961. doi:10.1245/s10434-012-2860-y Milano MT, Katz AW, Muhs AG, Philip A, Buchholz DJ, Schell MC, Okunieff P (2007) A prospective pilot study of curative-intent stereotactic body radiation therapy in patients with 5 or fewer oligometastatic lesions. Cancer Res 112:650–658 Fumagalli I, Bibault J-E, Dewas S, Kramar A, Mirabel X, Prevost B, Lacornerie T, Jerraya H, Lartigau E (2012) A single-institution study of stereotactic body radiotherapy for patients with unresectable visceral pulmonary or hepatic oligometastases. Radiat Oncol (London, England) 7:164. doi: 10.1186/1748-717X-7-164 Tree AC, Khoo VS, Eeles RA, Ahmed M, Dearnaley DP, Hawkins MA, Huddart RA, Nutting CM, Ostler PJ, van As NJ (2013) Stereotactic body radiotherapy for oligometastases. Lancet Oncol 14:e28–e37. doi:10.1016/S1470-2045(12)70510-7 Weichselbaum RR, Hellman S (2011) Oligometastases revisited. Nat Rev Clin Oncol 8:378–382. doi:10.1038/nrclinonc.2011.44 Corbin KS, Hellman S, Weichselbaum RR (2013) Extracranial oligometastases: a subset of metas. J Clin Oncol 31:1384–1390. doi:10.1200/JCO.2012.45.9651 Ashworth A, Rodrigues G, Boldt G, Palma D (2013) Is there an oligometastatic state in non-small cell lung cancer? A systematic review of the literature. Lung Cancer 82:197–203. doi:10.1016/j.lungcan.2013.07.026 Campbell PJ, Yachida S, Mudie LJ, Stephens PJ, Pleasance ED, Stebbings LA, Morsberger LA, Latimer C, McLaren S, Lin M-L, McBride DJ, Varela I, Nik-Zainal SA, Leroy C, Jia M, Menzies A, Butler AP, Teague JW, Griffin CA, Burton J, Swerdlow H, Quail MA, Stratton MR, Iacobuzio-Donahue C, Futreal PA (2010) The patterns and dynamics of genomic instability in metastatic pancreatic cancer. Nature 467:1109–1113. doi:10.1038/nature09460 Yachida S, Jones S, Bozic I, Antal T, Leary R, Fu B, Kamiyama M, Hruban RH, Eshleman JR, Nowak MA, Velculescu VE, Kinzler KW, Vogelstein B, Iacobuzio-Donahue CA (2010) Distant metastasis occurs late during the genetic evolution of pancreatic cancer. Nature 467:1114–1117. doi:10.1038/nature09515 Navin N, Kendall J, Troge J, Andrews P, Rodgers L, McIndoo J, Cook K, Stepansky A, Levy D, Esposito D, Muthuswamy L, Krasnitz A, McCombie WR, Hicks J, Wigler M (2011) Tumour evolution inferred by single-cell sequencing. Nature 472:90–94. doi:10.1038/nature09807 Gerlinger M, Rowan AJ, Horswell S, Larkin J, Endesfelder D, Gronroos E, Martinez P, Matthews N, Stewart A, Tarpey P, Varela I, Phillimore B, Begum S, McDonald NQ, Butler A, Jones D, Raine K, Latimer C, Santos CR, Nohadani M, Eklund AC, Spencer-Dene B, Clark G, Pickering L, Stamp G, Gore M, Szallasi Z, Downward J, Futreal PA, Swanton C (2012) Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. N Engl J Med 366:883–892. doi:10.1056/NEJMoa1113205 Klein CA (2013) Selection and adaptation during metastatic cancer progression. Nature 501:365–372. doi:10.1038/nature12628 Cairns J (1975) Mutation selection and the natural history of cancer. Nature 255:197–200 Nowell PC (1976) The clonal evolution of tumor cell populations. Science 194:23–28 Kim MY, Oskarsson T, Acharyya S, Nguyen DX (2009) Tumor self-seeding by circulating cancer cells. Cell 139(7):1315–1326 Bozic I, Antal T, Ohtsuki H, Carter H, Kim D, Chen S, Karchin R, Kinzler KW, Vogelstein B, Nowak MA (2010) Accumulation of driver and passenger mutations during tumor progression. Proc Natl Acad Sci USA 107:18545–18550. doi:10.1073/pnas.1010978107 Gupta GP, Massagué J (2006) Cancer metastasis: building a framework. Cell 127:679–695. doi:10.1016/j.cell.2006.11.001 Chiang AC, Massagué J (2008) Molecular basis of metastasis. N Engl J Med 359:2814–2823. doi:10.1056/NEJMra0805239 Valastyan S, Weinberg RA (2011) Tumor metastasis: molecular insights and evolving paradigms. Cell 147:275–292. doi:10.1016/j.cell.2011.09.024 Reymond N, d’Água BB, Ridley AJ (2013) Crossing the endothelial barrier during metastasis. Nat Rev Cancer 13:858–870. doi:10.1038/nrc3628 Hanahan D, Weinberg RA (2011) Hallmarks of cancer: the next generation. Cell 144:646–674. doi:10.1016/j.cell.2011.02.013 Khodarev NN, Yu J, Labay E, Darga T, Brown CK, Mauceri HJ, Yassari R, Gupta N, Weichselbaum RR (2003) Tumour-endothelium interactions in co-culture: coordinated changes of gene expression profiles and phenotypic properties of endothelial cells. J Cell Sci 116:1013–1022 Geng Y, Chandrasekaran S, Hsu J-W, Gidwani M, Hughes AD, King MR (2013) Phenotypic switch in blood: effects of pro-inflammatory cytokines on breast cancer cell aggregation and adhesion. PLoS One 8:e54959. doi:10.1371/journal.pone.0054959 Rückert F, Grützmann R, Pilarsky C (2012) Feedback within the inter-cellular communication and tumorigenesis in carcinomas. PLoS One 7:e36719. doi:10.1371/journal.pone.0036719 Khodarev NN, Roach P, Pitroda SP, Golden DW, Bhayani M, Shao MY, Darga TE, Beveridge MG, Sood RF, Sutton HG, Beckett MA, Mauceri HJ, Posner MC, Weichselbaum RR (2009) STAT1 pathway mediates amplification of metastatic potential and resistance to therapy. PLoS One 4:e5821. doi:10.1371/journal.pone.0005821 Efimova EV, Liang H, Pitroda SP, Labay E, Darga TE, Levina V, Lokshin A, Roizman B, Weichselbaum RR, Khodarev NN (2009) Radioresistance of Stat1 over-expressing tumour cells is associated with suppressed apoptotic response to cytotoxic agents and increased IL6-IL8 signalling. Int J Radiat Biol 85:421–431. doi:10.1080/09553000902838566 Pitroda SP, Zhou T, Sweis RF, Filippo M, Labay E, Beckett MA, Mauceri HJ, Liang H, Darga TE, Perakis S, Khan SA, Sutton HG, Zhang W, Khodarev NN, Garcia JGN, Weichselbaum RR (2012) Tumor endothelial inflammation predicts clinical outcome in diverse human cancers. PLoS One 7:e46104. doi:10.1371/journal.pone.0046104 Khodarev NN, Roizman B, Weichselbaum RR (2012) Molecular pathways: interferon/stat1 pathway: role in the tumor resistance to genotoxic stress and aggressive growth. Can. Res, Clin. doi:10.1158/1078-0432.CCR-11-3225 Kim VN (2005) MicroRNA biogenesis: coordinated cropping and dicing. Nat Rev Mol Cell Biol 6:376–385. doi:10.1038/nrm1644 Melo SA, Esteller M (2014) Disruption of microRNA nuclear transport in human cancer. Semin Cancer Biol. doi:10.1016/j.semcancer.2014.02.012 Chekulaeva M, Filipowicz W (2009) Mechanisms of miRNA-mediated post-transcriptional regulation in animal cells. Curr Opin Cell Biol 21:452–460. doi:10.1016/j.ceb.2009.04.009 Shen J, Xia W, Khotskaya YB, Huo L, Nakanishi K, Lim S-O, Du Y, Wang Y, Chang W-C, Chen C-H, Hsu JL, Wu Y, Lam YC, James BP, Liu X, Liu C-G, Patel DJ, Hung M-C (2013) EGFR modulates microRNA maturation in response to hypoxia through phosphorylation of AGO2. Nature 497:383–387. doi:10.1038/nature12080 Yang J-S, Smibert P, Westholm JO, Jee D, Maurin T, Lai EC (2013) Intertwined pathways for Argonaute-mediated microRNA biogenesis in Drosophila. Nucleic Acids Res. doi:10.1093/nar/gkt1038 Heravi-Moussavi A, Anglesio MS, Cheng S-WG, Senz J, Yang W, Prentice L, Fejes AP, Chow C, Tone A, Kalloger SE, Hamel N, Roth A, Ha G, Wan ANC, Maines-Bandiera S, Salamanca C, Pasini B, Clarke BA, Lee AF, Lee C-H, Zhao C, Young RH, Aparicio SA, Sorensen PHB, Woo MMM, Boyd N, Jones SJM, Hirst M, Marra MA, Gilks B, Shah SP, Foulkes WD, Morin GB, Huntsman DG (2012) Recurrent somatic DICER1 mutations in nonepithelial ovarian cancers. N Engl J Med 366:234–242. doi:10.1056/NEJMoa1102903 Witkos TM, Koscianska E, Krzyzosiak WJ (2011) Practical aspects of microRNA target prediction. Curr Mol Med 11:93–109 Lujambio A, Lowe SW (2012) The microcosmos of cancer. Nature 482:347–355. doi:10.1038/nature10888 Lovat F, Valeri N, Croce CM (2011) MicroRNAs in the pathogenesis of cancer. Semin Oncol 38:724–733. doi:10.1053/j.seminoncol.2011.08.006 Bendoraite A, Knouf EC, Garg KS, Parkin RK, Kroh EM, O’Briant KC, Ventura AP, Godwin AK, Karlan BY, Drescher CW, Urban N, Knudsen BS, Tewari M (2010) Regulation of miR-200 family microRNAs and ZEB transcription factors in ovarian cancer: evidence supporting a mesothelial-to-epithelial transition. Gynecol Oncol 116:117–125. doi:10.1016/j.ygyno.2009.08.009 Korpal M, Lee ES, Hu G, Kang Y (2008) The miR-200 family inhibits epithelial–mesenchymal transition and cancer cell migration by direct targeting of E-cadherin transcriptional repressors ZEB1 and ZEB2. J Biol Chem 283:14910–14914. doi:10.1074/jbc.C800074200 D’Amato NC, Howe EN, Richer JK (2013) MicroRNA regulation of epithelial plasticity in cancer. Cancer Lett 341:46–55. doi:10.1016/j.canlet.2012.11.054 Gregory PA, Bert AG, Paterson EL, Barry SC, Tsykin A, Farshid G, Vadas MA, Khew-Goodall Y, Goodall GJ (2008) The miR-200 family and miR-205 regulate epithelial to mesenchymal transition by targeting ZEB1 and SIP1. Nat Cell Biol 10:593–601. doi:10.1038/ncb1722 Ding X, Park SI, McCauley LK, Wang C-Y (2013) Signaling between transforming growth factor β (TGF-β) and transcription factor SNAI2 represses expression of microRNA miR-203 to promote epithelial–mesenchymal transition and tumor metastasis. J Biol Chem 288:10241–10253. doi:10.1074/jbc.M112.443655 Valastyan S, Weinberg RA (2011) Roles for microRNAs in the regulation of cell adhesion molecules. J Cell Sci 124:999–1006. doi:10.1242/jcs.081513 Valastyan S, Reinhardt F, Benaich N, Calogrias D, Szász AM, Wang ZC, Brock JE, Richardson AL, Weinberg RA (2009) A pleiotropically acting microRNA, miR-31, inhibits breast cancer metastasis. Cell 137:1032–1046. doi:10.1016/j.cell.2009.03.047 Penna E, Orso F, Cimino D, Tenaglia E, Lembo A, Quaglino E, Poliseno L, Haimovic A, Osella-Abate S, De Pittà C, Pinatel E, Stadler MB, Provero P, Bernengo MG, Osman I, Taverna D (2011) microRNA-214 contributes to melanoma tumour progression through suppression of TFAP2C. EMBO J 30:1990–2007. doi:10.1038/emboj.2011.102 Zhang Y-F, Zhang A-R, Zhang B-C, Rao Z-G, Gao J-F, Lv M-H, Wu Y-Y, Wang S-M, Wang R-Q, Fang D-C (2013) MiR-26a regulates cell cycle and anoikis of human esophageal adenocarcinoma cells through Rb1-E2F1 signaling pathway. Mol Biol Rep 40:1711–1720. doi:10.1007/s11033-012-2222-7 Aguda BD, Kim Y, Piper-Hunter MG, Friedman A, Marsh CB (2008) MicroRNA regulation of a cancer network: consequences of the feedback loops involving miR-17-92, E2F, and Myc. Proc Natl Acad Sci USA 105:19678–19683. doi:10.1073/pnas.0811166106 Northcott PA, Fernandez-L A, Hagan JP, Ellison DW, Grajkowska W, Gillespie Y, Grundy R, Van Meter T, Rutka JT, Croce CM, Kenney AM, Taylor MD (2009) The miR-17/92 polycistron is up-regulated in sonic hedgehog-driven medulloblastomas and induced by N-myc in sonic hedgehog-treated cerebellar neural precursors. Cancer Res 69:3249–3255. doi:10.1158/0008-5472.CAN-08-4710 Fish JE, Srivastava D (2009) MicroRNAs: opening a new vein in angiogenesis research. Sci Signal 2:pe1–pe1. doi: 10.1126/scisignal.252pe1 Guo C, Sah JF, Beard L, Willson JKV, Markowitz SD, Guda K (2008) The noncoding RNA, miR-126, suppresses the growth of neoplastic cells by targeting phosphatidylinositol 3-kinase signaling and is frequently lost in colon cancers. Genes Chromosom Cancer 47:939–946. doi:10.1002/gcc.20596 Liu Q, Lv G-D, Qin X, Gen Y-H, Zheng S-T, Liu T, Lu X-M (2012) Role of microRNA let-7 and effect to HMGA2 in esophageal squamous cell carcinoma. Mol Biol Rep 39:1239–1246. doi:10.1007/s11033-011-0854-7 Chan SY, Loscalzo J (2010) MicroRNA-210: a unique and pleiotropic hypoxamir. Cell Cycle 9:1072–1083 Pencheva N, Tavazoie SF (2013) Control of metastatic progression by microRNA regulatory networks. Nat Cell Biol 15:546–554. doi:10.1038/ncb2769 Lussier YA, Xing HR, Salama JK, Khodarev NN, Huang Y, Zhang Q, Khan SA, Yang X, Hasselle MD, Darga TE, Malik R, Fan H, Perakis S, Filippo M, Corbin K, Lee Y, Posner MC, Chmura SJ, Hellman S, Weichselbaum RR (2011) MicroRNA expression characterizes oligometastasis(es). PLoS One 6:e28650. doi:10.1371/journal.pone.0028650 Salama JK, Hasselle MD, Chmura SJ, Malik R, Mehta N, Yenice KM, Villaflor VM, Stadler WM, Hoffman PC, Cohen EEW, Connell PP, Haraf DJ, Vokes EE, Hellman S, Weichselbaum RR (2011) Stereotactic body radiotherapy for multisite extracranial oligometastases. Cancer Res 118:2962–2970. doi:10.1002/cncr.26611 Dykxhoorn DM, Wu Y, Xie H, Yu F, Lal A, Petrocca F, Martinvalet D, Song E, Lim B, Lieberman J (2009) miR-200 enhances mouse breast cancer cell colonization to form distant metastases. PLoS One 4:e7181. doi:10.1371/journal.pone.0007181 Korpal M, Ell BJ, Buffa FM, Ibrahim T, Blanco MA, Celià-Terrassa T, Mercatali L, Khan Z, Goodarzi H, Hua Y, Wei Y, Hu G, Garcia BA, Ragoussis J, Amadori D, Harris AL, Kang Y (2011) Direct targeting of Sec23a by miR-200 s influences cancer cell secretome and promotes metastatic colonization. Nat Med 17:1101–1108. doi:10.1038/nm.2401 Yoshino H, Enokida H, Itesako T, Tatarano S, Kinoshita T, Fuse M, Kojima S, Nakagawa M, Seki N (2013) Epithelial–mesenchymal transition-related microRNA-200s regulate molecular targets and pathways in renal cell carcinoma. J Hum Genet 58:508–516. doi:10.1038/jhg.2013.31 Wang X, Chen X, Wang R, Xiao P, Xu Z, Chen L, Hang W, Ruan A, Yang H, Zhang X (2013) microRNA-200c modulates the epithelial-to-mesenchymal transition in human renal cell carcinoma metastasis. Oncol Rep 30:643–650. doi:10.3892/or.2013.2530 Kurashige J, Kamohara H, Watanabe M, Hiyoshi Y, Iwatsuki M, Tanaka Y, Kinoshita K, Saito S, Baba Y, Baba H (2012) MicroRNA-200b regulates cell proliferation, invasion, and migration by directly targeting ZEB2 in gastric carcinoma. Ann Surg Oncol 19(Suppl 3):S656–S664. doi:10.1245/s10434-012-2217-6 Schliekelman MJ, Gibbons DL, Faca VM, Creighton CJ, Rizvi ZH, Zhang Q, Wong C-H, Wang H, Ungewiss C, Ahn Y-H, Shin D-H, Kurie JM, Hanash SM (2011) Targets of the tumor suppressor miR-200 in regulation of the epithelial–mesenchymal transition in cancer. Cancer Res 71:7670–7682. doi:10.1158/0008-5472.CAN-11-0964 Teng Y, Mei Y, Hawthorn L, Cowell JK (2014) WASF3 regulates miR-200 inactivation by ZEB1 through suppression of KISS1 leading to increased invasiveness in breast cancer cells. Oncogene 33:203–211. doi:10.1038/onc.2012.565 Guo L, Chen C, Shi M, Wang F, Chen X, Diao D, Hu M, Yu M, Qian L, Guo N (2013) Stat3-coordinated Lin-28-let-7-HMGA2 and miR-200-ZEB1 circuits initiate and maintain oncostatin M-driven epithelial–mesenchymal transition. Oncogene 32:5272–5282. doi:10.1038/onc.2012.573 Castilla MÁ, Moreno-Bueno G, Romero-Pérez L, De Vijver KV, Biscuola M, López-García MÁ, Prat J, Matías-Guiu X, Cano A, Oliva E, Palacios J (2010) Micro-RNA signature of the epithelial–mesenchymal transition in endometrial carcinosarcoma. J Pathol 223:72–80. doi:10.1002/path.2802 Harazono Y, Muramatsu T, Endo H, Uzawa N, Kawano T, Harada K, Inazawa J, Kozaki K-I (2013) miR-655 Is an EMT-suppressive MicroRNA targeting ZEB1 and TGFBR2. PLoS One 8:e62757. doi:10.1371/journal.pone.0062757.s012 Qiu X (2013) MiRNA-125a-3p is a negative regulator of the RhoA-actomyosin pathway in A549 cells. Int J Oncol 42:1734–1742. doi:10.3892/ijo.2013.1861 Qiao J, Lee S, Paul P, Theiss L, Tiao J, Qiao L, Kong A, Chung DH (2013) miR-335 and miR-363 regulation of neuroblastoma tumorigenesis and metastasis. Surgery 154:226–233. doi:10.1016/j.surg.2013.04.005 Anaya-Ruiz M, Bandala C, Perez-Santos JLM (2013) miR-485 acts as a tumor suppressor by inhibiting cell growth and migration in breast carcinoma T47D cells. Asian Pac J Cancer Prev 14:3757–3760 Vaira V, Faversani A, Dohi T, Montorsi M, Augello C, Gatti S, Coggi G, Altieri DC, Bosari S (2012) miR-296 regulation of a cell polarity-cell plasticity module controls tumor progression. Oncogene 31:27–38. doi:10.1038/onc.2011.209 Wu Z, Sun L, Wang H, Yao J, Jiang C, Xu W, Yang Z (2012) MiR-328 expression is decreased in high-grade gliomas and is associated with worse survival in primary glioblastoma. PLoS One 7:e47270. doi:10.1371/journal.pone.0047270.t003 Kim JK, Noh JH, Jung KH, Eun JW, Bae HJ, Kim MG, Chang YG, Shen Q, Park WS, Lee JY, Borlak J, Nam SW (2013) Sirtuin7 oncogenic potential in human hepatocellular carcinoma and its regulation by the tumor suppressors MiR-125a-5p and MiR-125b. Hepatology 57:1055–1067. doi:10.1002/hep.26101 Ding DP, Chen ZL, Zhao XH, Wang JW, Sun J, Wang Z, Tan FW, Tan XG, Li BZ, Zhou F, Shao K, Li N, Qiu B, He J (2011) miR-29c induces cell cycle arrest in esophageal squamous cell carcinoma by modulating cyclin E expression. Carcinogenesis 32:1025–1032. doi:10.1093/carcin/bgr078 Qiu T, Zhou X, Wang J, Du Y, Xu J, Huang Z, Zhu W, Shu Y, Liu P (2014) MiR-145, miR-133a and miR-133b inhibit proliferation, migration, invasion and cell cycle progression via targeting transcription factor Sp1 in gastric cancer. FEBS Lett 588:1168–1177. doi:10.1016/j.febslet.2014.02.054 Nakano H, Yamada Y, Miyazawa T, Yoshida T (2013) Gain-of-function microRNA screens identify miR-193a regulating proliferation and apoptosis in epithelial ovarian cancer cells. Int J Oncol 42:1875–1882. doi:10.3892/ijo.2013.1896 Guo X, Guo L, Ji J, Zhang J, Zhang J, Chen X, Cai Q, Li J, Gu Q, Liu B, Zhu Z, Yu Y (2010) miRNA-331-3p directly targets E2F1 and induces growth arrest in human gastric cancer. Biochem Biophys Res Commun 398:1–6. doi:10.1016/j.bbrc.2010.05.082 Xiao B, Tan L, He B, Liu Z, Xu R (2013) MiRNA-329 targeting E2F1 inhibits cell proliferation in glioma cells. J Transl Med 11:172. doi:10.1186/1479-5876-11-172 Zhai H, Song B, Xu X, Zhu W, Ju J (2012) Inhibition of autophagy and tumor growth in colon cancer by miR-502. Oncogene 32:1570–1579. doi:10.1038/onc.2012.167 Kim Y-K, Yu J, Han TS, Park S-Y, Namkoong B, Kim DH, Hur K, Yoo M-W, Lee H-J, Yang H-K, Kim VN (2009) Functional links between clustered microRNAs: suppression of cell-cycle inhibitors by microRNA clusters in gastric cancer. Nucleic Acids Res 37:1672–1681. doi:10.1093/nar/gkp002 Pickering MT, Stadler BM, Kowalik TF (2009) miR-17 and miR-20a temper an E2F1-induced G1 checkpoint to regulate cell cycle progression. Oncogene 28:140–145. doi:10.1038/onc.2008.372 Harazono Y, Muramatsu T, Endo H, Uzawa N, Kawano T, Harada K, Inazawa J, Kozaki K-I (2013) miR-655 Is an EMT-suppressive microRNA targeting ZEB1 and TGFBR2. PLoS One 8:e62757. doi:10.1371/journal.pone.0062757 Xin C, Zhang H, Liu Z (2014) miR-154 suppresses colorectal cancer cell growth and motility by targeting TLR2. Mol Cell Biochem 387:271–277. doi:10.1007/s11010-013-1892-3 Zhu C, Li J, Cheng G, Zhou H, Tao L, Cai H, Li P, Cao Q, Ju X, Meng X, Wang M, Zhang Z, Qin C, Hua L, Yin C, Shao P (2013) miR-154 inhibits EMT by targeting HMGA2 in prostate cancer cells. Mol Cell Biochem 379:69–75. doi:10.1007/s11010-013-1628-4 Zhu C, Shao P, Bao M, Li P, Zhou H, Cai H, Cao Q, Tao L, Meng X, Ju X, Qin C, Li J, Yin C (2014) miR-154 inhibits prostate cancer cell proliferation by targeting CCND2. Urol Oncol 32(31):e9–e16. doi:10.1016/j.urolonc.2012.11.013 Qu S, Yao Y, Shang C, Xue Y, Ma J, Li Z, Liu Y (2012) MicroRNA-330 is an oncogenic factor in glioblastoma cells by regulating SH3GL2 gene. PLoS One 7:e46010. doi:10.1371/journal.pone.0046010 Jeyapalan Z, Deng Z, Shatseva T, Fang L, He C, Yang BB (2011) Expression of CD44 3’-untranslated region regulates endogenous microRNA functions in tumorigenesis and angiogenesis. Nucleic Acids Res 39:3026–3041. doi:10.1093/nar/gkq1003 Swarbrick A, Woods SL, Shaw A, Balakrishnan A, Phua Y, Nguyen A, Chanthery Y, Lim L, Ashton LJ, Judson RL, Huskey N, Blelloch R, Haber M, Norris MD, Lengyel P, Hackett CS, Preiss T, Chetcuti A, Sullivan CS, Marcusson EG, Weiss W, L’Etoile N, Goga A (2010) miR-380-5p represses p53 to control cellular survival and is associated with poor outcome in MYCN-amplified neuroblastoma. Nat Med 16:1134–1140. doi:10.1038/nm.2227 Bao L, Hazari S, Mehra S, Kaushal D, Moroz K, Dash S (2012) Increased expression of P-glycoprotein and doxorubicin chemoresistance of metastatic breast cancer is regulated by miR-298. Am J Pathol 180:2490–2503. doi:10.1016/j.ajpath.2012.02.024 Anaya-Ruiz M, Cebada J, Delgado-López G, Sánchez-Vázquez ML, Perez-Santos JLM (2013) miR-153 silencing induces apoptosis in the MDA-MB-231 breast cancer cell line. Asian Pac J Cancer Prev 14:2983–2986 Myatt SS, Wang J, Monteiro LJ, Christian M, Ho K-K, Fusi L, Dina RE, Brosens JJ, Ghaem-Maghami S, Lam EW-F (2010) Definition of microRNAs that repress expression of the tumor suppressor gene FOXO1 in endometrial cancer. Cancer Res 70:367–377. doi:10.1158/0008-5472.CAN-09-1891 Zhao S, Deng Y, Liu Y, Chen X, Yang G, Mu Y, Zhang D, Kang J, Wu Z (2013) MicroRNA-153 is tumor suppressive in glioblastoma stem cells. Mol Biol Rep 40:2789–2798. doi:10.1007/s11033-012-2278-4 Yoon A-R, Gao R, Kaul Z, Choi I-K, Ryu J, Noble JR, Kato Y, Saito S, Hirano T, Ishii T, Reddel RR, Yun C-O, Kaul SC, Wadhwa R (2011) MicroRNA-296 is enriched in cancer cells and downregulates p21WAF1 mRNA expression via interaction with its 3’ untranslated region. Nucleic Acids Res 39:8078–8091. doi:10.1093/nar/gkr492 Savi F, Forno I, Faversani A, Luciani A, Caldiera S, Gatti S, Foa P, Ricca D, Bulfamante G, Vaira V, Bosari S (2014) MiR-296/Scribble axe is deregulated in human breast cancer and miR-296 restoration reduces tumor growth in vivo. Clin Sci 127:233–242. doi:10.1042/CS20130580 Bai Y, Liao H, Liu T, Zeng X, Xiao F, Luo L, Guo H, Guo L (2013) MiR-296-3p regulates cell growth and multi-drug resistance of human glioblastoma by targeting ether-à-go-go (EAG1). Eur J Cancer 49:710–724. doi:10.1016/j.ejca.2012.08.020 Wei JJ, Wu X, Peng Y, Shi G, Olca B, Yang X, Daniels G, Osman I, Ouyang J, Hernando E, Pellicer A, Rhim JS, Melamed J, Lee P (2011) Regulation of HMGA1 expression by MicroRNA-296 affects prostate cancer growth and invasion. Clin Cancer Res 17:1297–1305. doi:10.1158/1078-0432.CCR-10-0993 Li Q-Q, Chen Z-Q, Cao X-X, Xu J-D, Xu J-W, Chen Y-Y, Wang W-J, Chen Q, Tang F, Liu X-P, Xu Z-D (2011) Involvement of NF-κB/miR-448 regulatory feedback loop in chemotherapy-induced epithelial–mesenchymal transition of breast cancer cells. Cell Death Differ 18:16–25. doi:10.1038/cdd.2010.103 Wu Z-S, Wang C-Q, Xiang R, Liu X, Ye S, Yang X-Q, Zhang G-H, Xu X-C, Zhu T, Wu Q (2012) Loss of miR-133a expression associated with poor survival of breast cancer and restoration of miR-133a expression inhibited breast cancer cell growth and invasion. BMC Cancer 12:51. doi:10.1186/1471-2407-12-51 Kojima S, Chiyomaru T, Kawakami K, Yoshino H, Enokida H, Nohata N, Fuse M, Ichikawa T, Naya Y, Nakagawa M, Seki N (2012) Tumour suppressors miR-1 and miR-133a target the oncogenic function of purine nucleoside phosphorylase (PNP) in prostate cancer. Br J Cancer 106:405–413. doi:10.1038/bjc.2011.462 Yoshino H, Chiyomaru T, Enokida H, Kawakami K, Tatarano S, Nishiyama K, Nohata N, Seki N, Nakagawa M (2011) The tumour-suppressive function of miR-1 and miR-133a targeting TAGLN2 in bladder cancer. Br J Cancer 104:808–818. doi:10.1038/bjc.2011.23 Pan Y-Z, Morris ME, Yu A-M (2009) MicroRNA-328 negatively regulates the expression of breast cancer resistance protein (BCRP/ABCG2) in human cancer cells. Mol Pharmacol 75:1374–1379. doi:10.1124/mol.108.054163 Xu XT, Xu Q, Tong JL, Zhu MM, Nie F, Chen X, Xiao SD, Ran ZH (2012) MicroRNA expression profiling identifies miR-328 regulates cancer stem cell-like SP cells in colorectal cancer. Br J Cancer 106:1320–1330. doi:10.1038/bjc.2012.88 Paduano F, Dattilo V, Narciso D, Bilotta A, Gaudio E, Menniti M, Agosti V, Palmieri C, Perrotti N, Fusco A, Trapasso F, Iuliano R (2013) Protein tyrosine phosphatase PTPRJ is negatively regulated by microRNA-328. FEBS J 280:401–412. doi:10.1111/j.1742-4658.2012.08624.x Li W-Q, Li Y-M, Tao B-B, Lu Y-C, Hu G-H, Liu H-M, He J, Xu Y, Yu H-Y (2010) Downregulation of ABCG2 expression in glioblastoma cancer stem cells with miRNA-328 may decrease their chemoresistance. Med Sci Monit 16:HY27–HY30 Fang C, Zhao Y, Guo B (2013) MiR-199b-5p targets HER2 in breast cancer cells. J Cell Biochem 114:1457–1463. doi:10.1002/jcb.24487 Garzia L, Andolfo I, Cusanelli E, Marino N, Petrosino G, De Martino D, Esposito V, Galeone A, Navas L, Esposito S, Gargiulo S, Fattet S, Donofrio V, Cinalli G, Brunetti A, Vecchio LD, Northcott PA, Delattre O, Taylor MD, Iolascon A, Zollo M (2009) MicroRNA-199b-5p impairs cancer stem cells through negative regulation of HES1 in medulloblastoma. PLoS One 4:e4998. doi:10.1371/journal.pone.0004998 Andolfo I, Liguori L, De Antonellis P, Cusanelli E, Marinaro F, Pistollato F, Garzia L, De Vita G, Petrosino G, Accordi B, Migliorati R, Basso G, Iolascon A, Cinalli G, Zollo M (2012) The micro-RNA 199b-5p regulatory circuit involves Hes1, CD15, and epigenetic modifications in medulloblastoma. Neuro-oncology 14:596–612. doi:10.1093/neuonc/nos002 Ninio-Many L, Grossman H, Shomron N, Chuderland D, Shalgi R (2013) microRNA-125a-3p reduces cell proliferation and migration by targeting Fyn. J Cell Sci 126:2867–2876. doi:10.1242/jcs.123414 Chen J, Chen Y, Chen Z (2013) MiR-125a/b regulates the activation of cancer stem cells in paclitaxel-resistant colon cancer. Cancer Invest 31:17–23. doi:10.3109/07357907.2012.743557 Sun Y-M, Lin K-Y, Chen Y-Q (2013) Diverse functions of miR-125 family in different cell contexts. J Hematol Oncol 6:6. doi:10.1186/1756-8722-6-6 Bi Q, Tang S, Xia L, Du R, Fan R, Gao L, Jin J, Liang S, Chen Z, Xu G, Nie Y, Wu K, Liu J, Shi Y, Ding J, Fan D (2012) Ectopic expression of MiR-125a inhibits the proliferation and metastasis of hepatocellular carcinoma by targeting MMP11 and VEGF. PLoS One 7:e40169. doi:10.1371/journal.pone.0040169 Kim S-W, Ramasamy K, Bouamar H, Lin A-P, Jiang D, Aguiar RCT (2012) MicroRNAs miR-125a and miR-125b constitutively activate the NF-κB pathway by targeting the tumor necrosis factor alpha-induced protein 3 (TNFAIP3, A20). Proc Natl Acad Sci USA 109:7865–7870. doi:10.1073/pnas.1200081109 Yang H, Fang F, Chang R, Yang L (2013) MicroRNA-140-5p suppresses tumor growth and metastasis by targeting transforming growth factor β receptor 1 and fibroblast growth factor 9 in hepatocellular carcinoma. Hepatology 58:205–217. doi:10.1002/hep.26315 Fan Y-C, Mei P-J, Chen C, Miao F-A, Zhang H, Li Z-L (2013) MiR-29c inhibits glioma cell proliferation, migration, invasion and angiogenesis. J Neurooncol 115:179–188. doi:10.1007/s11060-013-1223-2 Wang H, Zhu Y, Zhao M, Wu C, Zhang P, Tang L, Zhang H, Chen X, Yang Y, Liu G (2013) miRNA-29c suppresses lung cancer cell adhesion to extracellular matrix and metastasis by targeting integrin β1 and matrix metalloproteinase2 (MMP2). PLoS One 8:e70192. doi:10.1371/journal.pone.0070192 Bae HJ, Noh JH, Kim JK, Eun JW, Jung KH, Kim MG, Chang YG, Shen Q, Kim S-J, Park WS, Lee JY, Nam SW (2013) MicroRNA-29c functions as a tumor suppressor by direct targeting oncogenic SIRT1 in hepatocellular carcinoma. Oncogene. doi: 10.1038/onc.2013.216 Wang C-M, Wang Y, Fan C-G, Xu F-F, Sun W-S, Liu Y-G, Jia J-H (2011) miR-29c targets TNFAIP3, inhibits cell proliferation and induces apoptosis in hepatitis B virus-related hepatocellular carcinoma. Biochem Biophys Res Commun 411:586–592. doi:10.1016/j.bbrc.2011.06.191 Liu N, Tang L-L, Sun Y, Cui R-X, Wang H-Y, Huang B-J, He Q-M, Jiang W, Ma J (2013) MiR-29c suppresses invasion and metastasis by targeting TIAM1 in nasopharyngeal carcinoma. Cancer Lett 329:181–188. doi:10.1016/j.canlet.2012.10.032 Kikkawa N, Hanazawa T, Fujimura L, Nohata N, Suzuki H, Chazono H, Sakurai D, Horiguchi S, Okamoto Y, Seki N (2010) miR-489 is a tumour-suppressive miRNA target PTPN11 in hypopharyngeal squamous cell carcinoma (HSCC). Br J Cancer 103:877–884. doi:10.1038/sj.bjc.6605811 Uhlmann S, Mannsperger H, Zhang JD, Horvat E-Á, Schmidt C, Küblbeck M, Henjes F, Ward A, Tschulena U, Zweig K, Korf U, Wiemann S, Sahin O (2012) Global microRNA level regulation of EGFR-driven cell-cycle protein network in breast cancer. Mol Syst Biol 8:570. doi:10.1038/msb.2011.100 Iliopoulos D, Rotem A, Struhl K (2011) Inhibition of miR-193a expression by Max and RXRα activates K-Ras and PLAU to mediate distinct aspects of cellular transformation. Cancer Res 71:5144–5153. doi:10.1158/0008-5472.CAN-11-0425 Ory B, Ramsey MR, Wilson C, Vadysirisack DD, Forster N, Rocco JW, Rothenberg SM, Ellisen LW (2011) A microRNA-dependent program controls p53-independent survival and chemosensitivity in human and murine squamous cell carcinoma. J Clin Invest 121:809–820. doi:10.1172/JCI43897 Kozaki KI, Imoto I, Mogi S, Omura K, Inazawa J (2008) Exploration of tumor-suppressive MicroRNAs silenced by DNA hypermethylation in oral cancer. Cancer Res 68:2094–2105. doi:10.1158/0008-5472.CAN-07-5194 Hsu K-W, Wang A-M, Ping Y-H, Huang K-H, Huang T-T, Lee H-C, Lo S-S, Chi C-W, Yeh T-S (2014) Downregulation of tumor suppressor MBP-1 by microRNA-363 in gastric carcinogenesis. Carcinogenesis 35:208–217. doi:10.1093/carcin/bgt285 Sun Q, Zhang J, Cao W, Wang X, Xu Q, Yan M, Wu X, Chen W (2013) Dysregulated miR-363 affects head and neck cancer invasion and metastasis by targeting podoplanin. Int J Biochem Cell Biol 45:513–520. doi:10.1016/j.biocel.2012.12.004